Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID

B. W M Van Bon, B. P. Coe, R. Bernier, C. Green, J. Gerdts, K. Witherspoon, T. Kleefstra, M. H. Willemsen, R. Kumar, P. Bosco, M. Fichera, D. Li, David G Amaral, F. Cristofoli, H. Peeters, E. Haan, C. Romano, H. C. Mefford, I. Scheffer, J. GeczB. B A De Vries, E. E. Eichler

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) maps to the Down syndrome critical region; copy number increase of this gene is thought to have a major role in the neurocognitive deficits associated with Trisomy 21. Truncation of DYRK1A in patients with developmental delay (DD) and autism spectrum disorder (ASD) suggests a different pathology associated with loss-of-function mutations. To understand the phenotypic spectrum associated with DYRK1A mutations, we resequenced the gene in 7162 ASD/DD patients (2446 previously reported) and 2169 unaffected siblings and performed a detailed phenotypic assessment on nine patients. Comparison of our data and published cases with 8696 controls identified a significant enrichment of DYRK1A truncating mutations (P=0.00851) and an excess of de novo mutations (P=2.53 × 10-10) among ASD/intellectual disability (ID) patients. Phenotypic comparison of all novel (n=5) and recontacted (n=3) cases with previous case reports, including larger CNV and translocation events (n=7), identified a syndromal disorder among the 15 patients. It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt. We conclude that mutations in DYRK1A define a syndromic form of ASD and ID with neurodevelopmental defects consistent with murine and Drosophila knockout models.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalMolecular Psychiatry
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Autistic Disorder
Intellectual Disability
Mutation
Febrile Seizures
Microcephaly
Gene Dosage
Fetal Growth Retardation
Down Syndrome
Drosophila
Siblings
Autism Spectrum Disorder
Pathology
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Van Bon, B. W. M., Coe, B. P., Bernier, R., Green, C., Gerdts, J., Witherspoon, K., ... Eichler, E. E. (2016). Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Molecular Psychiatry, 21(1), 126-132. https://doi.org/10.1038/mp.2015.5

Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. / Van Bon, B. W M; Coe, B. P.; Bernier, R.; Green, C.; Gerdts, J.; Witherspoon, K.; Kleefstra, T.; Willemsen, M. H.; Kumar, R.; Bosco, P.; Fichera, M.; Li, D.; Amaral, David G; Cristofoli, F.; Peeters, H.; Haan, E.; Romano, C.; Mefford, H. C.; Scheffer, I.; Gecz, J.; De Vries, B. B A; Eichler, E. E.

In: Molecular Psychiatry, Vol. 21, No. 1, 01.01.2016, p. 126-132.

Research output: Contribution to journalArticle

Van Bon, BWM, Coe, BP, Bernier, R, Green, C, Gerdts, J, Witherspoon, K, Kleefstra, T, Willemsen, MH, Kumar, R, Bosco, P, Fichera, M, Li, D, Amaral, DG, Cristofoli, F, Peeters, H, Haan, E, Romano, C, Mefford, HC, Scheffer, I, Gecz, J, De Vries, BBA & Eichler, EE 2016, 'Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID', Molecular Psychiatry, vol. 21, no. 1, pp. 126-132. https://doi.org/10.1038/mp.2015.5
Van Bon BWM, Coe BP, Bernier R, Green C, Gerdts J, Witherspoon K et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Molecular Psychiatry. 2016 Jan 1;21(1):126-132. https://doi.org/10.1038/mp.2015.5
Van Bon, B. W M ; Coe, B. P. ; Bernier, R. ; Green, C. ; Gerdts, J. ; Witherspoon, K. ; Kleefstra, T. ; Willemsen, M. H. ; Kumar, R. ; Bosco, P. ; Fichera, M. ; Li, D. ; Amaral, David G ; Cristofoli, F. ; Peeters, H. ; Haan, E. ; Romano, C. ; Mefford, H. C. ; Scheffer, I. ; Gecz, J. ; De Vries, B. B A ; Eichler, E. E. / Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. In: Molecular Psychiatry. 2016 ; Vol. 21, No. 1. pp. 126-132.
@article{2a8e51e82a044009a7772e02c6c95521,
title = "Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID",
abstract = "Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) maps to the Down syndrome critical region; copy number increase of this gene is thought to have a major role in the neurocognitive deficits associated with Trisomy 21. Truncation of DYRK1A in patients with developmental delay (DD) and autism spectrum disorder (ASD) suggests a different pathology associated with loss-of-function mutations. To understand the phenotypic spectrum associated with DYRK1A mutations, we resequenced the gene in 7162 ASD/DD patients (2446 previously reported) and 2169 unaffected siblings and performed a detailed phenotypic assessment on nine patients. Comparison of our data and published cases with 8696 controls identified a significant enrichment of DYRK1A truncating mutations (P=0.00851) and an excess of de novo mutations (P=2.53 × 10-10) among ASD/intellectual disability (ID) patients. Phenotypic comparison of all novel (n=5) and recontacted (n=3) cases with previous case reports, including larger CNV and translocation events (n=7), identified a syndromal disorder among the 15 patients. It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt. We conclude that mutations in DYRK1A define a syndromic form of ASD and ID with neurodevelopmental defects consistent with murine and Drosophila knockout models.",
author = "{Van Bon}, {B. W M} and Coe, {B. P.} and R. Bernier and C. Green and J. Gerdts and K. Witherspoon and T. Kleefstra and Willemsen, {M. H.} and R. Kumar and P. Bosco and M. Fichera and D. Li and Amaral, {David G} and F. Cristofoli and H. Peeters and E. Haan and C. Romano and Mefford, {H. C.} and I. Scheffer and J. Gecz and {De Vries}, {B. B A} and Eichler, {E. E.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/mp.2015.5",
language = "English (US)",
volume = "21",
pages = "126--132",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID

AU - Van Bon, B. W M

AU - Coe, B. P.

AU - Bernier, R.

AU - Green, C.

AU - Gerdts, J.

AU - Witherspoon, K.

AU - Kleefstra, T.

AU - Willemsen, M. H.

AU - Kumar, R.

AU - Bosco, P.

AU - Fichera, M.

AU - Li, D.

AU - Amaral, David G

AU - Cristofoli, F.

AU - Peeters, H.

AU - Haan, E.

AU - Romano, C.

AU - Mefford, H. C.

AU - Scheffer, I.

AU - Gecz, J.

AU - De Vries, B. B A

AU - Eichler, E. E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) maps to the Down syndrome critical region; copy number increase of this gene is thought to have a major role in the neurocognitive deficits associated with Trisomy 21. Truncation of DYRK1A in patients with developmental delay (DD) and autism spectrum disorder (ASD) suggests a different pathology associated with loss-of-function mutations. To understand the phenotypic spectrum associated with DYRK1A mutations, we resequenced the gene in 7162 ASD/DD patients (2446 previously reported) and 2169 unaffected siblings and performed a detailed phenotypic assessment on nine patients. Comparison of our data and published cases with 8696 controls identified a significant enrichment of DYRK1A truncating mutations (P=0.00851) and an excess of de novo mutations (P=2.53 × 10-10) among ASD/intellectual disability (ID) patients. Phenotypic comparison of all novel (n=5) and recontacted (n=3) cases with previous case reports, including larger CNV and translocation events (n=7), identified a syndromal disorder among the 15 patients. It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt. We conclude that mutations in DYRK1A define a syndromic form of ASD and ID with neurodevelopmental defects consistent with murine and Drosophila knockout models.

AB - Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) maps to the Down syndrome critical region; copy number increase of this gene is thought to have a major role in the neurocognitive deficits associated with Trisomy 21. Truncation of DYRK1A in patients with developmental delay (DD) and autism spectrum disorder (ASD) suggests a different pathology associated with loss-of-function mutations. To understand the phenotypic spectrum associated with DYRK1A mutations, we resequenced the gene in 7162 ASD/DD patients (2446 previously reported) and 2169 unaffected siblings and performed a detailed phenotypic assessment on nine patients. Comparison of our data and published cases with 8696 controls identified a significant enrichment of DYRK1A truncating mutations (P=0.00851) and an excess of de novo mutations (P=2.53 × 10-10) among ASD/intellectual disability (ID) patients. Phenotypic comparison of all novel (n=5) and recontacted (n=3) cases with previous case reports, including larger CNV and translocation events (n=7), identified a syndromal disorder among the 15 patients. It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt. We conclude that mutations in DYRK1A define a syndromic form of ASD and ID with neurodevelopmental defects consistent with murine and Drosophila knockout models.

UR - http://www.scopus.com/inward/record.url?scp=84951908030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951908030&partnerID=8YFLogxK

U2 - 10.1038/mp.2015.5

DO - 10.1038/mp.2015.5

M3 - Article

C2 - 25707398

AN - SCOPUS:84951908030

VL - 21

SP - 126

EP - 132

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -